Future developments in the pharmacotherapy of lung disease
- 16 Downloads
Future advances in the pharmacotherapy of lung disease will occur mainly in the treatment of asthma, and will include the development of new long-actingβ2-agonists, long-acting parasympatholytics, phosphodiesterase inhibitors, corticosteroids with fewer systemic side-effects, and other antiinflammatory drugs. Free radicals play an important role in most lung diseases, including asthma, emphysema, fibrosis, and adult respiratory distress syndrome. The search for free radical scavengers is now in progress. Replacement therapy with α1-antitrypsin and surfactant is now possible. Progress in this area stems principally from a better understanding of the pathogenesis of lung disease.
Keywordsβ2-Agonists, long-acting α1-Antitrypsin, deficiency Corticosteroids Free radical scavengers Parasympatholytics, long-acting Phosphodiesterase inhibitors Surfactant
Unable to display preview. Download preview PDF.
- 2.Van Schayck CP. Treatment of asthma and chronic bronchitis in patients from general practice [dissertation]. Nijmegen: Univ of Nijmegen, 1990.Google Scholar
- 3.Bown W. Warning letter links asthma death to drugs. New Scientist 1991;27 July.Google Scholar
- 9.Harding SM, Daniel MJ. The clinical pharmacology of inhaled fluticasone [abstract]. SEP-SEPCR Symposium; London, 12 Sept 1990.Google Scholar
- 10.Beume R, Schudt CH, Riedel R, Kilian U. Zardaverine — a new bronchodilator with anti-allergic and antiinflammatory activity? Eur Respir J 1989;2 Suppl 5:3993.Google Scholar
- 12.Kurihara K, Wardlaw AJ, Moqbel R, Kay AB. Inhibition of platelet activating fator, PAF-induced chemotaxis and PAF-binding to human eosinophils and neutrophils by a specific ginkgolide-derived PAF antagonist BN 52021. J Allergy Clin Immunol 1989;83:82–90.Google Scholar
- 13.Doelman CJA, Bast A. Oxygen radicals in lung pathology. Free Radical Biol Med 1990;9:381–400.Google Scholar
- 14.Thomas DA, Myers MA, Wiecert B, Schreier H, Gonzales Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 1991;99:1269–70.Google Scholar
- 15.Carell RW. The molecular structure and pathology of alpha 1 antitrypsin. Lung 1990;169 Suppl:530–4.Google Scholar
- 16.Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1 antitrypsin deficiency by the aerosol route. Lung 1990;169 Suppl:565–8.Google Scholar